225 related articles for article (PubMed ID: 16423166)
1. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Henderson DC; Kunkel L; Nguyen DD; Borba CP; Daley TB; Louie PM; Freudenreich O; Cather C; Evins AE; Goff DC
Acta Psychiatr Scand; 2006 Feb; 113(2):142-7. PubMed ID: 16423166
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
[TBL] [Abstract][Full Text] [Related]
4. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Karunakaran K; Tungaraza TE; Harborne GC
J Psychopharmacol; 2007 Jun; 21(4):453-6. PubMed ID: 17050662
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
6. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia.
Ziegenbein M; Sieberer M; Calliess IT; Kropp S
Aust N Z J Psychiatry; 2005 Sep; 39(9):840-1. PubMed ID: 16168043
[No Abstract] [Full Text] [Related]
7. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
Fleischhacker WW; Heikkinen ME; Olié JP; Landsberg W; Dewaele P; McQuade RD; Loze JY; Hennicken D; Kerselaers W
Int J Neuropsychopharmacol; 2010 Sep; 13(8):1115-25. PubMed ID: 20459883
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
9. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
11. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular aripiprazole in the control of agitation.
Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
[TBL] [Abstract][Full Text] [Related]
16. Benefits of combining aripiprazole to clozapine: three case reports.
Rocha FL; Hara C
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1167-9. PubMed ID: 16647796
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
18. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
[TBL] [Abstract][Full Text] [Related]
20. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
